Information Provided By: 
Fly News Breaks for April 26, 2016
SRPT
Apr 26, 2016 | 09:04 EDT
Baird analyst Brian Skorney thinks the chances of approval for eteplirsen on "this go-around" are 10% or less, but he continues to see more options for eteplirsen "beyond that of a make or break PDUFA outcome" next month. The analyst, who believes that the FDA and Sarepta may be able to agree on other options, such as cost recovery under an IND as an alternative, keeps an Outperform rating and $23 price target on Sarepta shares, which have been downgraded by at least three other firms this morning.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
